Anirban Adhikary1*, Kakoli Halder1, Debmalya Ghosh1, Snehansu Biswas2, Indranil Chatterjee2 and Suman Kumar Nath2
1B Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India
2Assistant Professor, Birbhum Pharmacy School, Birbhum, West Bengal, India
*Corresponding Author: Anirban Adhikary, B. Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India.
Received: August 24, 2020; Published: September 16, 2020
In December 2019, another coronavirus, named SARS-CoV-2, has risen up out of China causing pneumonia episodes first in the Wuhan locale and have now spread overall in view of its plausible high transmission productivity. Because of the absence of productive and explicit medicines and the need to contain the pestilence, medicate repurposing has all the earmarks of being the best instrument to discover remedial arrangement. Chloroquine, remdesivir, lopinavir, ribavirin or ritonavir have demonstrated viability to restrain coronavirus in vitro. Teicoplanin, an anti-microbial used to treat staphylococci disease, recently demonstrated adequacy to hinder the principal phase of MERS coronavirus viral cycle in human cells. This action is preserved on the SARS-Cov-2, accordingly putting teicoplanin as an expected treatment for patients with this infection.
Keywords: SARS-CoV-2; Drug Repurposing; Teicoplanin; COVID-19
Citation: Anirban Adhikary., et al. “A Review on Teicoplanin Used as Alternative Drug to Treat the Novel Corona Virus (COVID – 19)". Acta Scientific Microbiology 3.10 (2020): 59-60.
Copyright: © 2020 Anirban Adhikary., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.